Orchid Pharma Ltd approves Q2 FY27 results, reporting consolidated net profit of ₹28.59 crore
- Consolidated revenue was ₹341.27 crore, up 12.2% sequentially and 14.4% year on year; estimated EBITDA margin was 7.1%.
- Net profit compared with ₹3.22 crore in Q1 FY27 and a ₹0.90 crore loss in Q2 FY26.
- Standalone revenue was ₹341.27 crore and net profit ₹36.76 crore, with an estimated 6.8% EBITDA margin; auditors issued unmodified review conclusions, with no exceptional item reported.
